Drug Trial Radar · NCT07722546
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Jan 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells. In people with GD, the immune system produces abnormal antibodies, called thyroid-stimulating hormone receptor antibodies (TRAb), that attack the thyroid gland. This causes the thyroid to become too active and produce too much hormone, a condition called hyperthyroidism. Participants with GD are often treated with anti-thyroid drugs, or ATDs, which are medicines that help bring thyroid hormone levels back to normal. Felzartamab is designed to target certain immune cells that produce the abnormal TRAb antibodies. The main goal of the study is to learn whether felzartamab can help bring thyroid hormone levels back to normal and allow participants to stop taking ATDs. Participants will receive either felzartamab or placebo during the study. A placebo looks like the study drug but contains no real medicine. The main question that researchers want to answer is: • How many participants have normal thyroid levels without receiving any ATD medicine at Week 24? Researchers will also learn more about the safety of felzartamab and how the body processes the drug. The study will be done as follows: * Participants will be screened to check if they can join the study. * This is a double-blind study, which means neither the participants, study doctor, or site staff will know if participants are receiving felzartamab or a placebo. * Participants will be placed into 1 of 3 groups. Two groups will receive felzartamab while the other receives placebo. * Participants will receive felzartamab or placebo as intravenous (IV) infusions, which are slow injections into a vein using a needle. The Treatment Period will last 20 weeks. * During the Treatment Period, the study doctor may gradually lower the dose of the ATD if a participant's thyroid levels become normal. * Afterwards, participants will enter a follow-up period which will last 12 weeks. * In total, participants will have 22 study visits. Participants will stay in the study for about 9 months (up to 36 weeks).
Conditions
- Graves' Disease
Interventions
FelzartamabDrug
Administered IV
PlaceboDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who are Euthyroid and off Anti-Thyroid Drugs (ATD) at Week 24Time frame: At Week 24
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Sun City Clinical Research
Glendale, Arizona · Recruiting
AME Clinical Research
Los Angeles, California · Recruiting
San Jose Clinical Trials
San Jose, California · Recruiting
DM Clinical Research
Doral, Florida · Recruiting
LAMK Research and Health
Hialeah, Florida · Recruiting
Floridian Clinical Research - Clinitiative
Miami, Florida · Recruiting
Bioluminux Clinical Research
Naperville, Illinois · Recruiting
Patient First Clinical Trials (PFCTrials)
Lutherville, Maryland · Recruiting
Bioluminux Clinical Research
Hamilton, New Jersey · Recruiting
Asheville Clinical Research
Asheville, North Carolina · Recruiting
M3 Wake Research - Dallas
Dallas, Texas · Recruiting
Gulf Coast Clinical Research
Houston, Texas · Recruiting
Accurate Clinical Research, Inc
Humble, Texas · Recruiting
Patient First Clinical Trials (PFCTrials)
Richmond, Virginia · Recruiting
Solace Clinical Research - Puerto Rico
Bayamón, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.